Prophylactic Oxytocin Before Versus After Placental Delivery to Reduce

Status Recruiting

Clinical Trial Summary

Randomized controlled study to assess the efficacy and safety of the timing of administration of prophylactic oxytocin via intramuscular route (before compared to after placental delivery) on blood loss in vaginal delivery.

Clinical Trial Description

400 patients will be recruited for the study,Informed consent will be obtained from all patients following the research criteria once they are admitted in active labor, but they will be enrolled and randomized only when they reach the second stage of labor (fully dilated cervix) as it will be difficult in this stage to counsel patients.

The recruited patients will be subjected to the following:

- History taking: with particular emphasis on past medical history (especially for bleeding tendency), past obstetric history.

- Checking vital signs, General and abdominal examination.

- laboratory investigations: complete blood count (CBC)

- Findings of the initial obstetric evaluation follow up, labor duration and the need for oxytocin augmentation will be recorded through a partogram.

- All deliveries will be attended by a senior resident in the hospital.

- Included patients will receive the medication according to randomization tables.

- After allocation, patients will be excluded only if they required cesarean section, instrumental delivery or had multiple or deep vaginal tears that compromise estimation of uterine blood loss.

- All patients will undergo gentle traction to the umbilical cord while providing counter traction against the uterine fundus after signs of placental separation; appearance of bleeding, elongation of the cord.

- All patients will undergo cord clamping and cutting within 30 seconds of delivery.

- All patients will undergo uterine massage for 30 seconds after placental delivery.

- Vital signs (blood pressure and pulse) will be checked 15 minutes, 1 hour and 6 hours after placental delivery.

- CBC will be collected 6 hours after delivery. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03006380
Study type	Interventional
Source	Ain Shams Maternity Hospital
Contact	Reham Marie, MRCOG
Phone	+201212977339
Email	rehamfarghal84@gmail.com
Status	Recruiting
Phase	Phase 2
Start date	August 2016
Completion date	September 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03434444` - In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol	N/A
Terminated	`NCT01980173` - Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care	N/A
Not yet recruiting	`NCT06033170` - Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage	N/A
Completed	`NCT02163616` - Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study	Phase 3
Not yet recruiting	`NCT02319707` - Management of the Third Stage of Labor	Phase 3
Recruiting	`NCT01600612` - Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial	N/A
Completed	`NCT02079558` - Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section	Phase 2
Withdrawn	`NCT01108302` - Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India	N/A
Completed	`NCT00097123` - RCT of Misoprostol for Postpartum Hemorrhage in India	N/A
Completed	`NCT02883673` - Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage	N/A
Completed	`NCT02542813` - Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers	Phase 1
Completed	`NCT04201665` - EMG for Uterotonic Efficiency Estimation	N/A
Terminated	`NCT03246919` - Ideal Time of Oxytocin Infusion During Cesarean Section	Phase 4
Not yet recruiting	`NCT05501106` - Reducing Postpartum Hemorrhage After Vaginal Delivery	N/A
Completed	`NCT05429580` - Prophylactic Tranexamic Acid Use After Vaginal Delivery	N/A
Terminated	`NCT03064152` - Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery	N/A
Recruiting	`NCT05382403` - Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage	N/A
Completed	`NCT02910310` - Introduction of UBT for PPH Management in Three Countries	N/A
Completed	`NCT03344302` - Oxytocin Administration During Cesarean Section	Phase 4
Not yet recruiting	`NCT02853552` - Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Prophylactic Oxytocin Before Versus After Placental Delivery to Reduce Blood Loss in Vaginal Delivery

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms